World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

Auteurs:
Kivipelto, M, Mangialasche, F, Snyder, HM, Allegri R, Andrieu S, Arai H, Baker L, Belleville S*, Brodaty H, Brucki SM, Calandri I, Caramelli P, Chen C, Chertkow H*, Chew E, Choi SH, Chowdhary N, Crivelli L, De La Torre R, Du Y, Dua T, Espeland M, Feldman HH*, Hartmanis M, Hartmann T, Hefferman M, Henry CJ, Hong CH, Hâkansson K, Iwatsubo T, Jeong JH, Jimenez-Maggiora G, Koo EH, Launer LJ, Lehtisale J, Lopera F, Martinez-Lage P, Martins R, Middleton L, Molinuevo JL, Montero-Odasso M*, Moon SY, Morales-Perez K, Nitrine R, Nygaard HB*, Park YK, Peltonen M, Qiu C, Quiroz YT, Raman R, Rao N, Ravindranath V, Rosenberg A, Sakurai T, Salinas RM, Scheltens P, Sevlever G, Soininen H, Sosa AL, Suemoto CK, Tainta-Cuezva M, Velilla L, Wang Y, Whitmer R, Xu X, Bain LJ, Solomon A, Ngandu T, Carrillo M.
Revue:
Alzheimer's & Dementia
Année:

Abstract

Reducing the risk of dementia can halt the worldwide increase of affected people. The multifactorial and heterogeneous nature of late-onset dementia, including Alzheimer’s disease (AD), indicates a potential impact of multidomain lifestyle interventions on risk reduction. The positive results of the landmark multidomain Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) support such an approach.

The World-Wide FINGERS (WW-FINGERS), launched in 2017 and including over 25 countries, is the first global network of multidomain lifestyle intervention trials for dementia risk reduction and prevention.

WW-FINGERS aims to adapt, test, and optimize the FINGER model to reduce risk across the spectrum of cognitive decline-from at-risk asymptomatic states to early symptomatic stages-in different geographical, cultural, and economic settings. WW-FINGERS aims to harmonize and adapt multidomain interventions across various countries and settings, to facilitate data sharing and analysis across studies, and to promote international joint initiatives to identify globally implementable and effective preventive strategies.

NOTE: This is the first publication that uses data collected through the Can Thumbs Up platform. This is the description of the Canadian part of the WW-Fingers Study:

“In Canada, the Canadian Therapeutics Platform Trial for Multidomain Interventions to Prevent Dementia (CAN‐Thumbs‐Up) is in development and will include the recruitment of a platform trial‐ready cohort of participants identified as being at increased risk of dementia. This cohort will initially participate in an online Brain Health Support Program (BHSP) for up to 1 year, aimed at improving dementia literacy, self‐efficacy, and engagement. It will include remote assessments during the BHSP that will enable evaluation of compliance, and changes in lifestyle through this educational intervention. The platform trial‐ready cohort data will support the modeling of clinical and biomarker trajectories of the high‐risk participants, who initially will either be cognitively normal or have MCI. These data will inform development of the master trial protocol as well as permitting identification and tailoring of interventions to high risk study groups. The open platform trial will particularly focus on testing multidomain interventions, including treatments of lifestyle, pharmaceuticals, and other types of combination treatments in periods of up to 3 years. The primary outcome for the platform trial is expected to be a global cognitive composite, with a range of secondary and exploratory measures including blood‐based and digital biomarkers.”

More
Go back to top